Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis
Hepatology Research · 2026-06 · 56 (6) · 1016-1025
DOI: 10.1111/hepr.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 12.03.2026. Verfasst von Akihiko Shibamoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology of Nara Medical University, Nara, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Aim
The creatinine‐to‐cystatin C ratio (CCR) is considered a convenient surrogate marker for muscle mass, although its evidence in cirrhotic populations is limited. This study investigated the significance of CCR as a marker of sarcopenia in patients with cirrhosis.
Methods
Handgrip strength (HGS) and skeletal muscle mass index (SMI) were assessed in 195 patients with cirrhosis, divided into the sarcopenia ( n = 70) and nonsarcopenia ( n = 125) groups. Risk factors associated with sarcopenia were identified through multivariable logistic regression analyses.
Results
Sarcopenia was diagnosed in 70 out of 195 patients (35.9%). Patients with sarcopenia were significantly older, with lower body mass index (BMI), serum creatinine, and CCR, as well as higher albumin–bilirubin scores. Age ≥ 65 years, BMI < 25, and low CCR (< 0.63 in women, < 0.68 in men) were independently associated with sarcopenia on both univariable and multivariable analyses. The predictive accuracy of CCR for sarcopenia was comparable to that of a multivariable model combining age and BMI. On Kaplan–Meier analysis, overall survival was significantly lower in patients with low CCR (< 0.66) versus those with high CCR (≥ 0.66). Furthermore, HGS, SMI, and sarcopenia had comparable diagnostic value.
Conclusions
CCR is a simple, noninvasive biomarker for the diagnosis and prognosis of sarcopenia in patients with LC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology of Nara Medical University, Nara, Japan.
- Department of Evidence-Based Medicine, Nara Medical University, Nara, Japan.
- Clinical Research Center, Nara Medical University, Nara, Japan.
ORCID-Profile: Tadashi Namisaki, Satoshi Iwai, Norihisa Nishimura, Koh Kitagawa, Hiroaki Takaya, Kosuke Kaji, Akira Mitoro, Kiyoshi Asada, Hitoshi Yoshiji
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Shibamoto, A., Namisaki, T., Takami, M., Masuda, H., Inoue, T., Iwai, S., Asada, S., Tsuji, Y., Fujinaga, Y., Sato, S., Nishimura, N., Kitagawa, K., Takaya, H., Kaji, K., Mitoro, A., Asada, K., & Yoshiji, H. (2026). Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis. Hepatology Research, 56(6), 1016-1025. https://doi.org/10.1111/hepr.70156
Vancouver
Shibamoto A, Namisaki T, Takami M, Masuda H, Inoue T, Iwai S, et al. Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis. Hepatology Research. 2026;56(6):1016-1025. doi:10.1111/hepr.70156
BibTeX
@article{Shibamoto2026,
author = {Shibamoto, Akihiko and Namisaki, Tadashi and Takami, Masayoshi and Masuda, Hiroyuki and Inoue, Takashi and Iwai, Satoshi and Asada, Shohei and Tsuji, Yuki and Fujinaga, Yukihisa and Sato, Shinya and Nishimura, Norihisa and Kitagawa, Koh and Takaya, Hiroaki and Kaji, Kosuke and Mitoro, Akira and Asada, Kiyoshi and Yoshiji, Hitoshi},
title = {Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {6},
pages = {1016--1025},
doi = {10.1111/hepr.70156}
}
EUVIMED